Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 76

1.

BMP 9/10 in Pulmonary Vascular Complications of Liver Disease.

Rochon ER, Krowka MJ, Bartolome S, Heresi GA, Bull T, Roberts K, Hemnes A, Forde KA, Krok KL, Patel M, Lin G, McNeil M, Al-Naamani N, Roman BL, Yu PB, Fallon MB, Gladwin MT, Kawut SM; Pulmonary Vascular Complications of Liver Disease 2 (PVCLD2) Study Group.

Am J Respir Crit Care Med. 2020 Feb 21. doi: 10.1164/rccm.201912-2514LE. [Epub ahead of print] No abstract available.

PMID:
32083953
2.

Inhibition of bone morphogenetic protein 6 receptors ameliorates Sjögren's syndrome in mice.

Yin H, Kalra L, Lai Z, Guimaro MC, Aber L, Warner BM, Michael D, Zhang N, Cabrera-Perez J, Karim A, Swaim WD, Afione S, Voigt A, Nguyen CQ, Yu PB, Bloch DB, Chiorini JA.

Sci Rep. 2020 Feb 19;10(1):2967. doi: 10.1038/s41598-020-59443-z.

3.

Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.

Samokhin AO, Hsu S, Yu PB, Waxman AB, Alba GA, Wertheim BM, Hopkins CD, Bowman F, Channick RN, Nikolic I, Faria-Urbina M, Hassoun PM, Leopold JA, Tedford RJ, Ventetuolo CE, Leary PJ, Maron BA.

J Heart Lung Transplant. 2020 Apr;39(4):289-299. doi: 10.1016/j.healun.2019.12.002. Epub 2019 Dec 31.

PMID:
31952977
4.

Mesenchymal VEGFA induces aberrant differentiation in heterotopic ossification.

Hwang C, Marini S, Huber AK, Stepien DM, Sorkin M, Loder S, Pagani CA, Li J, Visser ND, Vasquez K, Garada MA, Li S, Xu J, Hsu CY, Yu PB, James AW, Mishina Y, Agarwal S, Li J, Levi B.

Bone Res. 2019 Dec 10;7:36. doi: 10.1038/s41413-019-0075-6. eCollection 2019.

5.

Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension.

Hodgson J, Swietlik EM, Salmon RM, Hadinnapola C, Nikolic I, Wharton J, Guo J, Liley J, Haimel M, Bleda M, Southgate L, Machado RD, Martin JM, Treacy CM, Yates K, Daugherty LC, Shamardina O, Whitehorn D, Holden S, Bogaard HJ, Church C, Coghlan G, Condliffe R, Corris PA, Danesino C, Eyries M, Gall H, Ghio S, Ghofrani HA, Gibbs JSR, Girerd B, Houweling AC, Howard L, Humbert M, Kiely DG, Kovacs G, Lawrie A, MacKenzie Ross RV, Moledina S, Montani D, Olschewski A, Olschewski H, Ouwehand WH, Peacock AJ, Pepke-Zaba J, Prokopenko I, Rhodes CJ, Scelsi L, Seeger W, Soubrier F, Suntharalingam J, Toshner MR, Trembath RC, Noordegraaf AV, Wort SJ, Wilkins MR, Yu PB, Li W, Gräf S, Upton PD, Morrell NW.

Am J Respir Crit Care Med. 2020 Mar 1;201(5):575-585. doi: 10.1164/rccm.201906-1141OC.

PMID:
31661308
6.

ST-Segment Elevation Myocardial Infarction Due to Right Coronary Artery Compression by Cardiac Synovial Sarcoma.

Atri DS, Tsao AL, Yu PB, Berry NC.

JACC Cardiovasc Interv. 2019 Sep 9;12(17):e145-e147. doi: 10.1016/j.jcin.2019.05.045. Epub 2019 Aug 14. No abstract available.

PMID:
31422086
7.

Application of in vitro Drug Metabolism Studies in Chemical Structure Optimization for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).

Padilha EC, Wang J, Kerns E, Lee A, Huang W, Jiang JK, McKew J, Mutlib A, Peccinini RG, Yu PB, Sanderson P, Xu X.

Front Pharmacol. 2019 Apr 24;10:234. doi: 10.3389/fphar.2019.00234. eCollection 2019.

8.

Letter by Morrell et al Regarding Article, "Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension".

Morrell NW, Upton PD, Li W, Yu PB.

Circ Res. 2019 Apr 26;124(9):e81. doi: 10.1161/CIRCRESAHA.119.314962. No abstract available.

PMID:
31021722
9.

Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials.

Wertheim BM, Lin YD, Zhang YY, Samokhin AO, Alba GA, Arons E, Yu PB, Maron BA.

PLoS One. 2019 Feb 27;14(2):e0211909. doi: 10.1371/journal.pone.0211909. eCollection 2019.

10.

In Search of the Second Hit in Pulmonary Arterial Hypertension.

Yang P, Yu PB.

Circ Res. 2019 Jan 4;124(1):6-8. doi: 10.1161/CIRCRESAHA.118.314270. No abstract available.

11.

Pharmacologic Strategies for Assaying BMP Signaling Function.

Dinter T, Bocobo GA, Yu PB.

Methods Mol Biol. 2019;1891:221-233. doi: 10.1007/978-1-4939-8904-1_16.

12.

Room With a View.

Yung LM, Yu PB.

Circ Cardiovasc Imaging. 2018 Aug;11(8):e008148. doi: 10.1161/CIRCIMAGING.118.008148. No abstract available.

13.

Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.

Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Troncone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, Zamanian RT, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):891-902. doi: 10.1164/rccm.201807-1236OC.

14.

Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.

Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W.

Bioorg Med Chem Lett. 2018 Nov 1;28(20):3356-3362. doi: 10.1016/j.bmcl.2018.09.006. Epub 2018 Sep 6.

15.

Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension.

Graham BB, Yu PB.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):9-11. doi: 10.1164/rccm.201808-1427ED. No abstract available.

PMID:
30130137
16.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

17.

Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association.

Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM.

Circ Res. 2018 May 11;122(10):1330-1333. doi: 10.1161/CIRCRESAHA.118.312999. No abstract available.

18.

Update in Pulmonary Vascular Disease 2016 and 2017.

Brittain EL, Thennapan T, Maron BA, Chan SY, Austin ED, Spiekerkoetter E, Bogaard HJ, Guignabert C, Paulin R, Machado RF, Yu PB.

Am J Respir Crit Care Med. 2018 Jul 1;198(1):13-23. doi: 10.1164/rccm.201801-0062UP. No abstract available.

19.

Correction for Bagarova et al., "Constitutively Active ALK2 Receptor Mutants Require Type II Receptor Cooperation".

Bagarova J, Vonner AJ, Armstrong KA, Börgermann J, Lai CSC, Deng DY, Beppu H, Alfano I, Filippakopoulos P, Morrell NW, Bullock AN, Knaus P, Mishina Y, Yu PB.

Mol Cell Biol. 2017 Sep 12;37(19). pii: e00284-17. doi: 10.1128/MCB.00284-17. Print 2017 Oct 1. No abstract available.

20.

Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.

Agarwal S, Loder SJ, Breuler C, Li J, Cholok D, Brownley C, Peterson J, Hsieh HH, Drake J, Ranganathan K, Niknafs YS, Xiao W, Li S, Kumar R, Tompkins R, Longaker MT, Davis TA, Yu PB, Mishina Y, Levi B.

Mol Ther. 2017 Aug 2;25(8):1974-1987. doi: 10.1016/j.ymthe.2017.01.008. Epub 2017 Jul 15.

Supplemental Content

Loading ...
Support Center